Daratumumab + Lenalidomide + Low-Dose Dexamethasone for Patients With Multiple Myeloma
January 26th 2021Sagar Lonial, MD, FACP, explains the importance of daratumumab/lenalidomide/low-dose dexamethasone (DRd) in several key areas, including progression-free survival versus common standard-of-care regimens in the PEGASUS trial, toxicities, and how active patients fare.
Watch
Considering Mutations and Resistance in Lung Cancer to Improve Precision Medicine
January 21st 2021Anne Chiang, MD, associate professor, Medical Oncology, Yale School of Medicine, discusses hard-to-treat lung cancer and how due to recent lung cancer innovations and treatment options, the tumor is becoming increasingly heterogeneous.
Watch